These findings clearly show that BPC 157 may successfully compete with the initial events in intra-abdominal hypertension (i.e., significant damage to the intestinal epithelium and dilation of intestinal tight junctions, increased mucosal barrier permeability, bacterial translocation, and sepsis (Luetic et al., 2017
Table 1 and Fig
In endothelial cells, BPC-157 activates ERK1/2 signaling, enhancing proliferation, migration, and vascular tube formation through transcription factors including c-Fos, c-Jun, and Egr-1
TB-500 remains a 503A Category-2 bulk substance, while BPC-157 was removed from the 503A list in April 2026 and is under PCAC review
Peripheral Neuropathy Megaloblastic Anaemia Read More Concerns Commonly asked questions How long does it take for this medicine to take effect
Some of these mechanisms are discussed below